The habitual way to read a clinical trial begins with the result: is there an effect, is it significant. Yet how much weight a result carries depends on how it was reached. A result assessed without reading the methods section almost always looks more certain than it is.
Randomisation and allocation concealment
Randomisation exists to make compared groups similar not only in what was measured but in what was not. Two separate questions belong here: how the sequence was generated, and whether the next allocation was concealed from the person enrolling the patient. Where concealment fails, decisions about who enters a study can create imbalance between groups without anyone intending it.
Blinding and the nature of the endpoint
How much blinding matters depends on the endpoint being measured. For hard endpoints such as death, the influence of assessor judgement is limited. For pain severity, quality of life, or endpoints resting on clinical assessment, the absence of blinding can systematically inflate an effect.
A pre-specified primary endpoint
When many endpoints are measured, the chance that at least one reaches significance by coincidence rises. This is why it matters that the primary endpoint was declared before the study began. Where the registry record and the published paper disagree about the primary endpoint, that discrepancy bears directly on how the result should be read.
Surrogate endpoints deserve separate care. An improvement in a laboratory value does not always correspond to an improvement a patient feels or experiences; the link between a surrogate and a clinical endpoint has to have been demonstrated in its own right.
Reading the size of an effect
Three measures are read together to judge what a result means in practice:
- Relative effect — the proportional change in risk.
- Absolute difference — the real difference between groups; a large relative reduction on a small baseline risk can mean a small absolute benefit.
- Confidence interval — the precision of the estimate; the width of the interval is more informative than a single point estimate.
A p-value alone describes neither the size nor the importance of an effect; it is a partial indicator of how compatible the observed difference is with chance.
Missing data and the analysis set
How participants who did not complete the study were handled can change the result. Analysing everyone who was randomised in the group to which they were assigned gives an estimate closer to real practice. Analysing only those who adhered fully to the protocol can make an effect look larger than it is. Where loss to follow-up is high, the choice between these approaches becomes decisive for how much the result can be trusted.
External validity
That a result is true does not mean it applies to every patient. Eligibility criteria, the age range studied, whether comorbidities were excluded, and the healthcare setting in which the study ran all determine to whom the finding can reasonably be generalised.
An order for reading
A useful sequence for methodological appraisal runs: the research question and design first, then the endpoint definitions, then randomisation and blinding, then participant flow and missing data, and the results last. Reading that starts at the results table makes limitations in the method harder to notice.
Reporting guidelines make this reading easier: CONSORT defines what should be reported for randomised trials and STROBE for observational studies. Missing elements do not by themselves show that a result is wrong, but they do show where an appraisal could not be carried out.
This is a general scientific information article; it is not an original research publication and does not constitute individual medical advice.